STENTYS Revenues For The First 9 Months Of 2013 Up 32% Over Prior Year

STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing ® stent to treat Acute Myocardial Infarction (AMI), today announced its revenues for third-quarter 2013 and 9-months through September 30, 2013.
  • Trends in quarterly and 9-month 2013 revenues*
               
  9 months Quarterly - 3 months
€ thousands

9 months 2013
     

9 months 2012
     

% change

Q3 2013
      Q3 2012      

% change
Revenues 2,406.6       1,823.2       +32.0% 768.0       673.6       +14.0%

* Data reviewed by statutory auditors
 

Revenues for the third quarter of 2013 totaled €768.0 thousand, up 14% compared to the third quarter of 2012. The substitution of paclitaxel by compounds of the “limus” family, deemed more efficient, on all coronary drug-eluting stents on the market may currently slow down the STENTYS paclitaxel-eluting stent’s entry into new accounts and has yielded a more moderate growth rate this quarter. The first clinical results from the STENTYS Sirolimus-eluting stent (“limus” family) will be presented on October 29, and its commercialization outside of the United States is expected after CE Mark approval by the end of 2014.